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Background: The sixth leading class of cancer worldwide is head and neck cancer, which typically arise within the
squamous epithelium of the oral mucosa. Human head and neck squamous cell carcinoma (HNSCC) is known to be
difficult to treat and has only a 50% five-year survival rate. With HNSCC, novel therapeutics are needed along with a
means of rapidly screening anti-cancer agents in vivo, such as mouse models.
Methods: In order to develop new animal models of cancer to test safety and efficacy of novel therapeutic agents for
human HNSCC, tumors resembling clinical cases of human HNSCC were induced in the head and neck epithelium of a
genetically engineered mouse model. This mouse model was generated by conditional deletion of two tumor
suppressors, Transforming Growth Factor-β Receptor 1 (TGFβRI) and Phosphatase and Tensin homolog (PTEN), in the
oral epithelium. We discovered that the tumors derived from these Tgfbr1/Pten double conditional knockout (2cKO)
mice over-expressed IL-13Rα2, a high affinity receptor for IL-13 that can function as a tumor antigen. To demonstrate a
proof-of-concept that targeted therapy against IL-13Rα2 expression would have any antitumor efficacy in this
spontaneous tumor model, these mice were treated systemically with IL-13-PE, a recombinant immunotoxin consisting
of IL-13 fused to the Pseudomonas exotoxin A.
Results: Tgfbr1/Pten 2cKO mice when treated with IL-13-PE displayed significantly increased survival when compared
to the untreated control mice. The untreated mice exhibited weight loss, particularly with the rapid onset of tongue
tumors, but the treated mice gained weight while on IL-13-PE therapy and showed no clinical signs of toxicity due to
the immunotoxin. Expression of IL-13Rα2 in tumors was significantly decreased with IL-13-PE treatment as compared
to the controls and the number of myeloid-derived suppressor cells (MDSC) was also significantly reduced in the
spleens of the IL-13-PE treated mice.
Conclusions: Our study demonstrates that the Tgfbr1/Pten 2cKO mouse model of human HNSCC is a useful model for
assessing antitumor activity of new cancer therapeutic agents, and that IL-13-PE has therapeutic potential to treat
human head and neck cancer.
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In order to test new therapies for the prevention and
treatment of head and neck squamous cell carcinoma
(HNSCC), we generated a novel mouse model that mimics
clinical cases of human head and neck cancer [1]. Our
mouse model of HNSCC allows for conditional deletion of
two important tumor suppressors in the oral epithelium:
Transforming Growth Factor-β Receptor 1 (TGFβRI), an
inhibitor of epithelial proliferation, and phosphatase
and tensin homolog (PTEN), an enzyme that negatively
regulates PI3K/Akt signaling to prevent uncontrolled
cell growth. Patients with human HNSCC often display
alterations in the cellular signaling pathways associated
with these two tumor suppressors [2-4]. Upon deletion
of both TGFβRI and PTEN, the resulting double condi-
tional knockout (2cKO) mice develop papillomas as early
as 4 weeks after tumor induction, and these tumors
progress to squamous cell carcinomas with 100% pene-
trance. The majority of the Tgfbr1/Pten 2cKO mice
develop tumors on the epithelium of the tongue, although
tumors also form elsewhere on the head and neck epi-
thelium such as the ears and muzzle area. The tumors
in the Tgfbr1/Pten 2cKO mice display many of the same
biochemical alterations that are common to human
HNSCC, particularly with regard to upregulation of
inflammatory cytokines that promote tumor growth
and proliferation.
Since HNSCC accounts for about 8% of newly diagnosed
cancers worldwide [5] with an overall 5-year survival rate
of only 40–50% in patients despite recent advances in
multimodality therapy [6], novel therapeutic agents are
needed that will increase overall survival while avoiding
the toxicities associated with current radiotherapy and
chemotherapy. We have previously reported that IL-13R
α2, a receptor that binds IL-13 with high affinity, is
uniquely overexpressed on some human head and neck
cancers. The expression of the IL-13 receptors has been
shown to be significantly higher in HNSCC than in normal
tissues with a tissue array. In particular, about 33% of
human HNSCCs display moderate to high-level expression
of IL-13Rα2 [7]. The expression of IL-13Rα2, a unique
receptor that binds IL-13 with high affinity and involved
in signaling in cancer cells, is over expressed in cancer
while its expression is mostly absent or low on other
tissues except expression in testicular tissue [8]. We
therefore, examined tumors from the Tgfbr1/Pten 2cKO
mice for expression of IL-13Rα2 in order to establish
any further link between our mouse model and human
cases of HNSCC. We discovered that this receptor is
overexpressed within the squamous cell carcinomas of
the mice. With this knowledge of IL-13Rα2 upregulation
in the tumors, we hypothesized that our mouse model
could be used to study targeted therapy against this
cancer marker.One therapy that can be used to target expression of
the IL-13Rα2 tumor antigen involves the use of a novel
recombinant immunotoxin, designated IL-13-PE, which
consists of the IL-13 cytokine fused to the Pseudomonas
exotoxin A (PE) [9]. IL-13-PE has been shown to have
cytotoxic effects against head and neck cancer cell lines
that are either positive for IL-13Rα2 or are stably
transfected to express IL-13Rα2. Anti-tumor activity was
demonstrated with IL-13-PE in an immunodeficient
xenograft mouse model using these human HNSCC
cell lines and the immunotoxin treatment were well-
tolerated by the mice [10]. With the sensitivity of these
HNSCC cell lines to IL-13-PE, we decided to test this
immunotoxin treatment in a genetically engineered
mouse model of head and neck cancer, the Tgfbr1/Pten
2cKO mice. Because secretion of IL-13 can influence
tumor suppressor cells including myeloid derived
supressor cells leading to immunoevasion [11,12], testing
IL-13-PE in the immunocompetent Tgfbr1/Pten 2cKO
mice will allow us to study the effects of this treatment
on the tumor microenvironment, particularly the
interactions with the immune system. Also, there is a
known interplay between IL-13 and TGF-β signaling
[13,14], so it will additionally be interesting to examine
IL-13-PE treatment in a context where, similar to a sub-
set of human HNSCC patients, the cancer cells are un-
affected by the growth inhibitory effects of TGF-β1 and
can thereby utilize this cytokine to create a tumor-
promoting microenvironment. So, HNSCC was induced
in the Tgfbr1/Pten 2cKO mouse model and mice were
dosed with IL-13-PE to determine the therapeutic effect
of this treatment. The Tgfbr1/Pten 2cKO mice that
received IL-13-PE treatment had significantly increased
longevity as compared to the controls. These results sug-
gest that our spontaneous immunocompetent head and
neck tumor model is useful for testing cancer therapeutics
and that IL-13-PE could be a useful treatment regimen for
inhibiting the growth of human HNSCC.
Materials and methods
Tgfbr1/Pten 2cKO mice
The Tgfbr1/Pten 2cKO mice (K14-CreERtam; Tgfbr1f/f/
Ptenf/f) were generated as previously described [1]. Essen-
tially, tamoxifen (200 μl at a concentration of 10 μg/μl in
corn oil) was applied to the oral cavity of 5- to 7-week-old
K14-CreERtam; Tgfbr1f/f/Ptenf/f mice to induce the K14-
CreERtam transgene which causes deletion of TGFβRI
and PTEN in the head and neck epithelium. Tumors
developed in 100% of the mice as early as 4 weeks after
conditional deletion of these tumor suppressors. When
the lesions reached 2 cm, or became ulcerated, the
animals were euthanized and a necropsy was performed.
Mice were also euthanized in the survival studies if
animals exhibited any signs of excessive weight loss
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proper eating. All care to the mice was given in compli-
ance with the National Institutes of Health guidelines
on the use of laboratory and experimental animals, and
the studies were approved by the National Institute of
Dental and Craniofacial Research (NIDCR) Animal Care
and Use Committee (ACUC).
IL-13-PE treatment
A recombinant fusion IL-13 immunotoxin termed as IL-
13-PE, consisting of human IL-13 and a mutated form
of Pseudomonas exotoxin, was purified in our laboratory
as described previously [9]. Since human IL-13 binds to
murine cells, this fusion protein was used in murine
experiments [15]. IL-13-PE was administered to the
Tgfbr1/Pten 2cKO mice by i.p. injection in a volume of
500 μl (50 μg/kg) in 0.2% human serum albumin in PBS
[10]. The i.p. schedule included two injections per day
(b.i.d.) at a minimum interval of 6–8 hr on alternate
days for two weeks (a total of 12 injections per mouse).
Cell culture and protein synthesis inhibition assay
Primary cultures were established as previously described
[16]. Excised tumors from the Tgfbr1/Pten 2cKO mice were
enzymatically digested (10 mg/ml collagenase, 1 mg/ml
hyaluronidase, and 0.5 mg/ml DNAse [Sigma-Aldrich,
St. Louis, MO]) and the isolated tumor cells were
cultured in RPMI1640 medium containing 10% FBS. After
two to three passages, tumor cells were treated with IL-
13-PE and cytotoxicity was measured. Essentially, 104
cells were cultured with or without various concentrations
of IL-13-PE for 22 hours in a leucine-free medium and
then incubated with 1 μCi of [3H] leucine (NEN Research
Products, Waltham, MA) for an additional 4 hours.
Following these incubation times, the uptake of the radio-
active leucine was measured using a Beta plate counter
(Wallace, Waltham, MA).
Histology and immunohistochemistry
Tumors along with control tissues such as buccal mucosa,
tongue, spleen, lung, kidney, and liver were carefully
dissected from the mice and fixed overnight in 10%
buffered formalin. The tissues were embedded in paraffin
and 5-μm sections were used for histopathological ana-
lysis. Tumor pathology was examined using slides stained
with hematoxylin and eosin (H&E). For immunohisto-
chemistry, sections were deparaffinized in xylene, re-
hydrated with descending grades of ethanol, blocked for
30 min, and incubated with primary antibody (see below)
prepared in Background Reducing Antibody Diluent (Dako,
Carpentaria, CA). Next, the sections were treated with the
Rabbit on Rodent HRP-Polymer (Biocare, Concord, CA)
or with a biotinylated secondary antibody (Vector Labora-
tories, Burlingame, CA) followed by treatment with theVectastain ABC reagent (Vector Laboratories). Antibody
complexes were detected using liquid DAB (Biogenex,
Fremont, CA). Primary antibody dilutions are as follows:
1:100 dilution for anti-mouse IL-13Rα2 (R&D Systems,
Inc., Minneapolis, MN), and 1:100 dilutions for phospho-
Akt (Ser473) (D9E) antibody (Cell Signaling, Danvers, MA)
and Anti-Mouse Ki-67 Antigen Clone TEC-3 (Dako,
Carpentaria, CA).
Western blot analysis
Tumors and normal epithelium from the buccal mucosa
and tongue were collected from Tgfbr1/Pten 2cKO and
Tgfbr1f/f/Ptenf/f mice, and protein lysates were generated
using T-PER reagent (Pierce, Rockford, IL) with a complete
mini protease inhibitor cocktail (Roche, Branchburg, NJ).
About 50 μg of the extracted protein were denatured and
then separated with electrophoresis on NuPAGE 4-12%
Bis-Tris precast gels using XCell surelock Mini-Cell
(Invitrogen, Carlsbad, CA). Proteins were then trans-
ferred onto a nitrocellulose membrane, blocked for 1
hour, and incubated with primary antibodies overnight.
The attached antibodies were then visualized using a horse-
radish peroxidase-conjugated secondary antibody (Santa
Cruz, Santa Cruz, CA) followed by chemiluminescence de-
tection (Pierce, Rockford, IL). Subsequently, all blots were
re-incubated with anti-Actin antibody (1:5000 dilution;
Millipore, Billerica, MA) as a loading control. The following
primary antibody dilutions were used: 1:250 for muIL-13R
α2 (R&D Systems, Inc., Minneapolis, MN) and 1:1000 for
phospho-Akt (Ser473) (D9E), and, phospho-Stat3 (Tyr705)
(D3A7), antibodies (Cell Signaling, Danvers, MA).
Quantitative real-time PCR
Total RNA was extracted from the tongue tumors and
adjacent control tongue tissue using 3 pairs of Tgfbr1/
Pten 2cKO mice as well as a Tgfbr1f/f/Ptenf/f control.
RNA was isolated using the miRNeasy Mini kit (Qiagen,
Valencia, CA). For mRNA analysis, 0.5 μg of total RNA
were reverse transcribed into cDNA and a tenth of this
solution was then used per well with iQ SYBR Green
Supermix (Bio-Rad, Hercules, CA) for real-time PCR
(RT-PCR). Samples were run in quadruplicate using a
Chromo4 PCR System (Bio-Rad). The IL-13 receptors
(IL-13Rα2, IL-13Rα1, IL-4Rα) and a β-actin internal con-
trol were detected using QuantiTect Primers (Qiagen,
Valencia, CA). RT-PCR to detect IL-13Rα2 expression
on the primary tumor cultures was performed as previ-
ously described [16].
Flow cytometric analysis
Splenocytes were isolated from three Tgfbr1/Pten 2cKO
mice immediately following IL-13-PE treatment and then
compared to the appropriate controls. Quantification of
MDSCs (CD11b+ GR-1+) by FACS analysis was performed
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were evaluated using FITC-conjugated anti-CD11b and
PerCP-Cy5.5–conjugated anti–Gr-1 Abs (e-Bioscience, San
Diego, CA). All flow cytometric analyses were performed
on a FACSCanto II (Becton Dickinson, San Jose, CA) flow
cytometer.Statistical analysis
The data was analyzed for statistical significance using
Graph Pad Prism version 5.00 for Windows (Graph-Pad
Software Inc, La Jolla, CA). Survival curves were generated
using the Kaplan-Meier method and compared using the
Log-rank (Mantel-Cox) Test. Two-way ANOVA was used
to compare the weight change between IL-13-PE treated
and untreated groups. A two-tailed Student’s unpaired
t test was used to determine statistical significance for
all other comparisons including the determination of
significant differences in receptor expression by real-
time PCR, IL-13Rα2 expression by Western blot, and
numbers of MDSCs using FACS.Results
Expression of IL-13Rα2 in Tgfbr1/Pten 2cKO mouse with
HNSCC
Deletion of TGFβRI and PTEN in the oral epithelium of
mice has been shown to lead to the formation of spon-
taneous tumors that resemble human HNSCC, including
similar tumor promoting alterations in various cell sig-
naling pathways [1]. As previously reported the tumors
in these mice look like human HNSCC pathologically
with atypical cells and differentiated keratin pearls. The
mouse tumors also mirror the same molecular alterations
found in human HNSCC such as EGFR overexpression
and activated Akt, NF-κB, and Stat3 signaling. Since
IL-13Rα2 is over-expressed in about 33% of human
HNSCCs [7], we decided to examine the tumors of
these mice for this unique cancer marker. Western
blot showed that IL-13Rα2 is upregulated in the tumors
of the Tgfbr1/Pten 2cKO mice (Figure 1A). Immunohis-
tochemistry analysis also showed staining of SCC from
tongue and muzzle tumors but not in the normal tongue
(Figure 1B). As previously described, HNSCC in the
Tgfbr1/Pten 2cKO mice can be identified with activated
Akt due to PTEN deletion, along with phosphorylated
Stat3, both cell signaling pathways that are commonly
activated in human HNSCC [1]. These two markers were
used to verify that the IL-13Rα2 expression is primarily
restricted to the HNSCC. The tumors that arise because
of TGFβRI and PTEN deletion occur not only on the
tongues of the mice, but also on the head and neck epithe-
lium around the ears and the muzzle. Regardless of
location, all squamous cell carcinomas displayed high
expression of IL-13Rα2, making the mouse model idealfor studying targeted cytotoxin therapy against IL-13Rα2.
Using real-time PCR, we also examined three sets of
mice for the expression of transcripts for various chains
of receptors, e.g. IL-13Rα2, IL-13Rα1, and IL-4Rα,
which are involved in IL-13 receptor structure and func-
tion. We observed an upregulation of the transcripts of
all three subunit receptors in the tongue tumors, as
compared to the normal corresponding adjacent tongue
tissue (Figure 1C). Expression of the IL-13 receptors
was significantly higher in the tongue tumors from the
Tgfbr1/Pten 2cKO mice (P value < 0.0001) when compared
with the normal tongue tissue in whichTGFBR1 and PTEN
was not genetically deleted.
Cytotoxicity of IL-13-PE on primary tumor cells from
Tgfbr1/Pten 2cKO mice
Since IL-13Rα2 binds to IL-13 with high affinity and
then undergoes internalization, expression of this recep-
tor can thereby be targeted for delivery of a bacterial
toxin into a cancer cell [18]. The therapeutic agent IL-
13-PE was designed to bind to cells expressing IL-13
receptors and cause selective cytotoxicitiy upon intern-
alization. Primary cultures were derived from the tumors
of the Tgfbr1/Pten 2cKO mice to determine if the up-
regulated expression of IL-13Rα2 by the cancer cells
would make them sensitive to the IL-13-PE cytotoxicity.
The isolated primary cancer cells from the Tgfbr1/Pten
2cKO mice retain higher expression of IL-13Rα2 as
compared to other tissues, including the spleen, lung,
kidney, liver, and skin (Figure 2A). Higher expression of
IL-13Rα2 is therefore primarily limited to the tumor
cells and does not appear to be aberrantly triggered in
any other tissues through the tumor induction process,
which causes conditional deletion of TGFβRI and PTEN.
As seen in Figure 2B, the cultured primary tumor cells
with upregulated IL-13Rα2 were sensitive to the addition
of IL-13-PE in a dose-dependent manner. Using two
Tgfbr1/Pten 2cKO mice, each with multiple tumor sites,
an IC50 (the concentration of drug causing 50% inhibition
of protein synthesis) ranging between 45–100 ng/ml was
determined for IL-13-PE. For this in vitro testing, PM-
RCC was selected as a positive control out of many cell
lines tested because of higher expression of high-affinity
IL-13Rα2. Based on sensitivity (IC50) of primary cells to
IL-13-PE, these cells most likely express lower number
of IL-13 receptors. We have not tested affinity of IL-13-PE
binding on these cells. However, in previous studies, we
demonstrated that higher binding affinity of IL-13-PE to
tumor cells did not enhance cytotoxicity to cells because
internalization of only few molecules of IL-13-PE was
enough to kill the cells [19]. The primary tumor cultures
seem to have an intermediate expression of IL-13Rα2
where the IC50 for these cells is similar to the murine sar-
coma cell line MCA304, which has moderate sensitivity to
Figure 1 Upregulation of IL-13Rα2 in tumors from Tgfbr1/Pten 2cKO mice. (A) Western blot analysis showing upregulation of IL-13Rα2 in
multiple squamous cell carcinomas (SCC) which develop from loss of Tgfbr1/Pten in the head and neck epithelium. Tumors can be identified by
increases in both p-Akt, genetically induced with Pten deletion, and in p-Stat3, a commonly activated signaling pathway in HNSCC. (B) Positive
immunohistochemical analysis showing IL-13Rα2 staining on two representative SCCs as compared to the normal tongue epithelium. (C) Real-time
PCR shows increases in mRNA of all IL-13 receptor subunits between three pairs of tongue tumors and the normal tongue tissue (P value < 0.0001 in
most cases).
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don’t display IL-13Rα2, were unaffected by IL-13-PE treat-
ment. It is to be noted that cytotoxicity of IL-13-PE toward
IL-13Rα2 positive cells is highly specific as we have shown
in our previous several studies that an excess of IL-13
(100–200 fold) neutralizes activity of IL-13-PE [10,21].
IL-13-PE treatment of Tgfbr1/Pten 2cKO mice
With confirmation of the cytotoxic effects of IL-13-PE
on cultured primary murine HNSCC tumor cells, we
next decided to treat Tgfbr1/Pten 2cKO mice with i.p.
injections of the recombinant immunotoxin. The dosing
schedule of IL-13-PE administration is illustrated in
Figure 3A. Essentially, tumors were induced in mice
between 5 to 7 weeks of age using daily oral adminis-
tration of Tamoxifen for five days to promote the re-
combinase activity of the K14-CreERtam transgene. The
K14-CreERtam in turn causes recombination in the
Tgfbr1f/f and Ptenf/f alleles and disrupts the expressionof these two important tumor suppressors. Treatment
with IL-13-PE was then initiated four weeks from the
day tumor induction began, since papillomas and early
carcinomas generally start to appear at this time in
the Tgfbr1/Pten 2cKO mouse. The Tgfbr1/Pten 2cKO
mice were dosed with two i.p. injections of IL-13-PE
(50 μg/kg) per day (b.i.d.) at a minimum interval of
6–8 hr on alternate days for two weeks. The dose
selected for this study was less than the maximum
tolerated dose for IL-13-PE based on several previous
mouse experiments [10]. The preclinical safety studies
characterizing the organ toxicities stemming from
higher doses of IL-13-PE have already been described
previously [22,23]. The Tgfbr1/Pten 2cKO mice treated
with IL-13-PE (n=25) showed increased survival (p=0.002)
compared to the littermate controls that were injected
only with excipient (0.2% human serum albumin in PBS)
(n=23) (Figure 3B). IL-13-PE was administered to the mice
as they first started to succumb to tumor-associated
Figure 2 Sensitivity of primary tumor cultures to IL-13-PE treatment. (A) RT-PCR shows that IL-13Rα2 expression is high for the primary
cultures but low in other tissues from Tgfbr1/Pten 2cKO mice undergoing tumor induction. (B) Primary cultures are sensitive to the cytotoxic
effects of IL-13-PE, as measured by a decrease in protein synthesis. An IC50 for IL-13-PE ranged between 45–100 ng/ml in the primary cultured
tumor cells overexpressing IL-13Rα2.
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The median survival significantly increased from 69 days
after tumor induction in the controls to about 92 days
through IL-13-PE treatment. At day 90, around the day of
the median survival, 14 out of 25 (or 56%) survived in
the IL-13-PE treatment group compared to 5 out of 23
(or 21%) in control group. More than twice as many
treated mice were surviving at this time point as
compared to the controls, clearly indicating the delay in
progression of disease. In these survival studies, about
65% of the mice develop tongue tumors that impair the
ability to eat and therefore cause cachexia. The mice
given the IL-13-PE therapy had roughly the same occur-
rence of tongue tumors as the controls, so the
immunotoxin treatment most likely delayed the develop-
ment of these tumors, which accounts for the increased
survival. As previously reported, metastasis was not
observed in the Tgfbr1/Pten 2cKO cancer model because
of the rapid growth and progression of the carcinomas
that develop in these mice, so the effects of IL-13-PE
treatment on metastasis could not be observed [1].
The IL-13-PE administration was well-tolerated by the
Tgfbr1/Pten 2cKO mice and the mice treated with
cytotoxin therapy showed improvements in their health,
as opposed to the control littermates. In the few mice
that had tumors at the onset of IL-13-PE treatment, the
tumors appeared to regress after immunotoxin adminis-
tration, in contrast to the untreated mice. Mice treated
with IL-13-PE continued to gain weight while the controlslost weight due to the developing head and neck
tumors (P value < 0.0001; Figure 3C). In particular,
mice with carcinomas on the tongue lost weigh due to
an inability to eat properly. No histological toxicity was
detected in association with IL-13-PE treatment in
tissues such as the spleen, lung, and heart (data not
shown), which thereby demonstrated the restricted
targeting of the IL-13-PE cytotoxin to only the cancer
cells and not the normal tissues. The receptor-targeted
specificity of IL-13-PE has been shown earlier by using an
irrelevant IL2-PE immunotoxin as a control. IL2-PE, a
immunotoxin known to exert its cytotoxicity through
binding to IL-2 receptor γ chain was not cytotoxic to
IL-13Rα2 positive tumor cells confirming that IL-13
-PE-mediated cytotoxicity is IL-13Rα2 specific [24].
Decreased expression of IL13Rα2 after IL-13-PE treatment
Immunotoxin therapy by IL-13-PE will essentially target
cancer cells that upregulate IL-13Rα2 and will therefore
select against its expression. We looked at the tumor
tissues from treated Tgfbr1/Pten 2cKO mice to see if
the expression of IL-13Rα2 was decreased. Expression
of IL-13Rα2 was variable in the tumors collected from
the Tgfbr1/Pten 2cKO mice but was generally decreased
overall in the IL-13-PE treated mice (Figure 4A). In the
IL-13-PE treated mice, the levels of IL-13Rα2 were sig-
nificantly decreased in tumors that developed on the
head and neck epithelia such as the muzzle and ears
(P value < 0.05; Figure 4B), but no significant difference
Figure 3 Increased survival in Tgfbr1/Pten 2cKO mice dosed with IL-13-PE. (A) A schematic showing the dosing schedule of IL-13-PE to
Tgfbr1/Pten 2cKO mice. (B) Survival curve shows increased longevity in Tgfbr1/Pten 2cKO mice treated with IL-13-PE (measured in days
following tumor induction). Median survival increased from 69 days in the controls to 92 days with IL-13-PE treatment (P value = 0.002 Log-rank
[Mantel-Cox] Test). (C) The treated mice continue gaining weight after IL-13-PE therapy as compared to the control mice (P value < 0.0001
Two-way ANOVA).
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(data not shown). Decreased expression of IL-13Rα2 in
the tumors was also detected through immunohisto-
chemical analysis (Figure 4C) but, of the cancer cells that
evaded cell death by IL-13-PE, no difference in prolif-
eration could be seen with Ki67 staining as compared to
the untreated mice. In addition, IL-13-PE had no signifi-
cant effect on phosphorylation of Akt, a tumor promoting
kinase that is irreversibly activated in the Tgfbr1/Pten
2cKO mice due to genetically Cre-mediated PTEN dele-
tion. No association could be made between the level of
IL-13Rα2 on a tumor and the time since administering
IL-13-PE treatment. Treatment with IL-13-PE at an
early time point in cancer development may have se-
lectively hindered the growth and establishment of
high IL-13Rα2 expressing cancer cells in the mice,
resulting in the formation of tumors with decreased
overall expression of this receptor.Reduction in MDSCs but not Tregs through IL-13-PE
treatment
The expression of IL-13Rα2 has been linked to deleteri-
ous immune effect such as tumor immune evasion, par-
ticularly since signaling through this receptor causes
upregulation of the immunosuppressive cytokine TGF-
β1 [11,12]. To examine for any immunological changes
in the treated mice, some animals were sacrificed three
days after the last dose of IL-13-PE, and FACS analysis
was performed using the splenocytes. The MDSCs, a
heterogeneous population of myeloid cells known to
promote tumor immune evasion, were detected with
FACS analysis using the monocyte/macrophage markers
CD11b+ and the granulocyte antigen Gr-1+ [17]. The
Tgfbr1f/f/Ptenf/f mice lacking the K14-CreERtam trans-
gene to cause conditional deletion were also analyzed
as normal controls without tumors. As expected, the
numbers of MDSCs in the spleens increased from
Figure 4 Decreased IL-13Rα2 expression through IL-13-PE immunotoxin treatment. (A) Western blot showing decreased expression of IL-
13Rα2 in SCCs from IL-13-PE treated mice when compared to the corresponding control SCCs. Tumors developed from different locations in the
head and neck epithelium such as the tongue, muzzle, and ear. (B) Tumors from the muzzle and ear of the IL-13-PE treated mice show a
significant decrease (P value < 0.05) in relative IL-13Rα2 expression compared to the non-treated mice. (C) Immunohistochemistry shows a
general decrease in IL-13Rα2 expression on a tumor from the ear of an IL-13-PE treated mouse as compared to the control but, of the cancer
cells that escaped cell death by IL-13-PE, there was no change in p-Akt, a genetic change induced by Pten deletion, nor was there any difference
in active proliferation through Ki67 staining.
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untreated Tgfbr1/Pten 2cKO mice due to deletion of
TGFβRI and PTEN and to the subsequent tumor de-
velopment. Interestingly, the number of MDSCs dropped
by half to 15.5% (P < 0.005) with IL-13-PE treatment
(Figure 5B). A representative FACS plot is shown in
Figure 5A.
Although the number of MDSCs decreased with IL-
13-PE treatment, no significant change was seen in the
number of macrophages from the spleens of the mice
(data not shown). Another immunosuppressive popula-
tion of cells, T regulatory cells (Tregs), also showed no
change between the two groups of mice (data not shown).
The MDSCs, however, may be particularly sensitive to
IL-13-PE treatment since IL-13Rα2 has been shown to
express on some populations of these myeloid cells in
order to induce TGF-β1 secretion and promote tumor
immune evasion [11].
Discussion
In order to aid in the discovery of new treatments
and mechanisms of human HNSCC actions, we have
developed a mouse model that spontaneously forms
tumors in the head and neck epithelium with 100%penetrance. We observed that these tumors mimic human
HNSCC with similar morphology and altered cell signal-
ing. With such resemblance to human HNSCCs, the
Tgfbr1/Pten 2cKO mice could be useful for screening
novel therapeutics against cancer. Cancer cells often
overexpress cell surface receptors of both growth factors
and cytokines that help promote tumor growth, prolif-
eration, and immune evasion. As previously shown, IL-13R
α2 is upregulated in about 33% of human HNSCC [7] but
remains absent or shows very low expression on normal
cells. Our previous in vitro studies showed that IL-13Rα2-
positive HNSCC cell lines were sensitive to cytotoxic effect
of IL-13-PE depending upon the level of their expression of
IL-13Rα2 chain. The specificity and requirement of
IL-13Rα2 chain for cytotoxicity was further confirmed
by transient transfection of IL-13Rα2 chain in two IL-
13Rα2-negative HNSCC cell lines. Both transfectants
acquired sensitivity to IL-13-PE confirming the rele-
vance of the utility of IL-13-PE in head and neck can-
cer therapy [25]. We demonstrate that tumors from
Tgfbr1/Pten 2cKO mice express high levels of not
only IL-13Rα2, but of IL-13Rα1 and IL-4Rα as well.
We have previously shown that cultured cells derived
from the periorbital and perianal squamous cell
Figure 5 MDSCs were decreased by IL-13-PE treatment in Tgfbr1/Pten 2cKO mice. (A) Representative flow profile showing decreased
populations of CD11b+Gr-1+ cells through IL-13-PE treatment. (B) Quantification of flow cytometry results. IL-13-PE treated mice are compared
with both the saline injected Tgfbr1/Pten 2cKO tumor-bearing controls and the Tgfbr1f/f/Ptenf/f mice without tumors. MDSCs were significantly
reduced with IL-13-PE treatment (P value < 0.005).
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tional knockout model can also express IL-13Rα2 and
are sensitive to IL-13-PE treatment [16]. Future stud-
ies will be conducted to determine if TGFβRI deletion
facilitates IL-13Rα2 expression on squamous cell carcin-
omas. Because cell surface receptors can be targeted with
monoclonal antibodies and fusion toxins, we tested
whether the expression of the IL-13 receptors in tumors
derived from Tgfbr1/Pten 2cKO mice can be targeted as
part of a strategy to treat HNSCC. We found that a re-
combinant IL-13-PE immunotoxin targeting IL-13Rα2
has remarkable anti-cancer activity against these tumors.
IL-13-PE immunotoxin is specifically designed to tar-
get tumors expressing this receptor by combining the
IL-13 cytokine with the Pseudomonas exotoxin [9]. Bac-
terial toxins are ideal for generating immunotoxins since
they can be easily produced in E. coli and show few side
effects in humans if properly targeted [26]. Upon endo-
cytosis, the fusion toxin translocates to the cytosol and
inactivates elongation factor 2 to cause cell death. IL-
13Rα2 is also an ideal target for cytotoxin-based therapy
since it is a unique tumor target displaying a high affin-
ity for IL-13 and undergoes endocytosis upon binding.
These qualities minimize the uptake of IL-13-PE by nor-
mal cells. Targeting IL-13Rα2 expression may also be
useful in restoring proper immunosurveillance [11].
As an anti-cancer strategy, IL-13-PE immunotoxin treat-
ment has already proven to be efficacious against tumors
in many cancer mouse models and is currently being used
in clinical trials. IL-13-PE was used in a Phase 3 clinical
study to treat patients with glioblastoma multiforme, an-
other cancer type wherein IL-13Rα2 is overexpressed in
the majority of tumor cells. Convection-enhanced delivery
of IL-13-PE was well-tolerated by patients with malignant
gliomas [27]. One challenge of immunotoxin and any
targeted therapy is efficient penetration into solid tumors.Nevertheless, in the Tgfbr1/Pten 2cKO mouse model
of HNSCC, systemic administration of IL-13-PE resulted
in significantly increased survival in the treated mice as
compared to the untreated controls. Tumor regression
was evident in the few mice that had visible tumors at
the start of IL-13-PE, particularly in the SCCs around
the muzzle. Unlike the controls, the mice treated with
the IL-13-PE group did not experience the immediate
weight loss that typically occurs during tongue tumor
development due to obstructed eating. However, both
groups of mice in the survival studies eventually had the
same occurrence of SCCs on the tongue, suggesting a
possible delay in the formation and growth of these
tumors. The weight gain together with the lack of any
histological signs of toxicity also demonstrate that the
IL-13-PE treatment is well-tolerated by the mice. In our
recent study on the role of IL-13Rα2 in pancreatic can-
cer invasion and metastasis, we demonstrated that IL-
13Rα2–positive cancer metastasized to lymph nodes,
liver, and peritoneum at a significantly higher rate
compared with IL-13Rα2–negative tumors. The level of
IL-13Rα2 expression in metastatic lesion was higher
compared to the primary tumors [28]. Though we did
not investigate the presence of metastasis in this model,
the pancreatic tumor cells collected from lymph nodes
metastasis were much more sensitive to IL-13-PE in vitro
than compared with primary tumor cells indicating higher
level of IL-13Rα2 in metastatic lesion. Based on this data,
we can predict similar efficacy of IL-13-PE to eliminate
metastatic lesions common in patients with HNSCC.
Future studies will be conducted to determine the opti-
mal schedule and dose of administration of IL-13-PE.
It is interesting to note that IL-13Rα2 expression was
decreased in the tumors of IL-13-PE treated mice, indi-
cating that high IL-13Rα2 positive cells are eliminated
while IL-13Rα2 negative or low expressing tumors were
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not cause any impact on proliferation of tumor cells as
no difference in Ki67 staining was observed in tumors of
treated mice compared to those of the untreated mice.
To examine the mechanism of antitumor response by
IL-13-PE, we investigated whether treatment affected
immunosurveillance to subsequently allow for enhanced
tumor destruction by the immune system. IL-13-PE
treatment caused a significant decrease in MDSCs in the
spleen of treated mice that corresponded with increased
survival. On the other hand, another immunosuppressive
population of cells, Tregs, showed no change in the
spleens between the two groups of mice (data not
shown). This may be due to a direct cytotoxic effect of
IL-13-PE on MDSCs, since some of these myeloid cells
are known to express IL-13Rα2 in order to induce TGF-
β1 secretion and promote tumor immune evasion [12].
Future studies will examine the status of MDSCs and T
regs in various tumors of these mice. However, it is
possible that the reduction in the number of MDSCs
resulted in improved immunosurveillance and, conse-
quently, enhanced survival of the animals.
Taken together, the results from the Tgfbr1/Pten 2cKO
mice validate our previous report on nude mice with
transplanted tumors, which suggests that IL-13-PE may
be an effective therapeutic agent for the treatment of
HNSCC. Along with delaying tumor formation, we were
able to see in the immunocompetent Tgfbr1/Pten 2cKO
mice that the IL-13-PE treatment could additionally
limit the development of an immunosuppressive tumor
environment. Other treatment delivery options for
IL-13-PE could improve the effectiveness of this
immunotoxin in the Tgfbr1/Pten 2cKO mice such as
direct injection into the head and neck tumors or a sur-
gically implanted continuous infusion pump [22]. IL-13
-PE has also been shown to work synergistically with
paclitaxel in an immunodeficient animal model of
HNSCC [29] with gemcitabine for pancreatic cancer
[30] and a DNA vaccine of IL-13Rα2 in melanoma,
breast, and sarcoma tumor models [20]. It is therefore
possible that any of these combinations would be useful
for testing the Tgfbr1/Pten 2cKO mouse model of spon-
taneous cancer. Further studies will be performed to test
this combination approach. In summary, our study
demonstrates that our HNSCC mouse model is valuable
for developing novel cancer therapeutic approaches [31],
and that IL-13-PE has therapeutic potential to treat
human head and neck cancer.
Conclusion
Conditional deletion of both TGFβRI and PTEN in the
oral cavity of mice results in the formation of spontaneous
squamous cell carcinomas in the head and neck area that
display IL-13Rα2, a tumor antigen expressed in 33% ofhuman HNSCCs. Primary cultures from the Tgfbr1/Pten
2cKO mouse tumors show sensitivity to IL-13-PE. The
Tgfbr1/Pten 2cKO mice were therefore tested with IL-
13-PE (50 μg/kg b.i.d. on alternate days) for two weeks
starting at an early point in tumor induction when car-
cinomas are first beginning to appear. This IL-13-PE
regimen significantly increased survival in the tumor
bearing mice (P value 0.002) with no signs of toxicity.
Expression of IL-13Rα2 was reduced in the tumors
while, concurrently, the spleens of the treated mice
show reduced numbers of MDSCs, a population of mye-
loid cells that aid in tumor immune evasion. The
increased survival of the IL-13-PE treated mice helps to
further validate the idea that targeted therapy against
IL-13Rα2 expression could be employed as a clinical
means of inhibiting HNSCC.
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